Expertise in
30
conditions

Dr. Amitkumar Mehta

Hematology
University Of Alabama Health Services Foundation PC
2000 6th Ave S, 
Birmingham, AL 
Offers Telehealth
Expertise in
30
conditions
University Of Alabama Health Services Foundation PC
2000 6th Ave S, 
Birmingham, AL 

Overview

Amitkumar Mehta is a Hematologist in Birmingham, Alabama. Dr. Mehta is highly rated in 30 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Tissue Biopsy.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in AL

Hospital Affiliations

University Of Alabama Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

University of Alabama Health Services Foundation PC
2000 6th Ave S, Birmingham, AL 35233
Other Locations
Office
1720 2nd Ave S, Birmingham, AL 35294

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Siltuximab
Study Phase: Phase 2
A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies
A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drug: BR101801
Study Phase: Phase 1
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Biological
Study Drugs: TAK-007, Chemotherapy Agents
Study Phase: Phase 2
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: SEA-TGT, Pembrolizumab
Study Phase: Phase 1
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

81 Total Publications

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma.
Journal: Future oncology (London, England)
Published: December 10, 2025
Similar Doctors
Andres Torres
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology
Expertise in
23
conditions
Dr. Andres Torres
Hematology | Oncology

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-996-6074
Languages Spoken:
English
See accepted insurances

Andres Torres is a Hematologist and an Oncologist in Birmingham, Alabama. Dr. Torres is highly rated in 23 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Breast Cancer, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Bone Marrow Aspiration.

Expertise in
23
conditions
Dr. Luciano Costa
Hematology
Expertise in
23
conditions
Dr. Luciano Costa
Hematology

UAB Hospital Birmingham

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luciano Costa is a Hematologist in Birmingham, Alabama. Dr. Costa is highly rated in 23 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
24
conditions
Dr. Pankit Vachhani
Hematology
Expertise in
24
conditions
Dr. Pankit Vachhani
Hematology

University Of Alabama Health Services Foundation PC

2000 6th Ave S, 
Birmingham, AL 
 (0.2 miles away)
205-975-0412
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pankit Vachhani is a Hematologist in Birmingham, Alabama. Dr. Vachhani is highly rated in 24 conditions, according to our data. His top areas of expertise are Myelofibrosis, Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Amitkumar Mehta

How do I make an appointment with Dr. Amitkumar Mehta?

You can book an appointment with Dr. Amitkumar Mehta by calling their office at 205-801-8415. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amitkumar Mehta a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amitkumar Mehta is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amitkumar Mehta specialize in?

While Dr. Amitkumar Mehta is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Amitkumar Mehta participate in research or clinical trials?

Yes. Dr. Amitkumar Mehta has published 81 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Amitkumar Mehta's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amitkumar Mehta accept my insurance?

Dr. Amitkumar Mehta accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 205-801-8415 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehta's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 14 Advanced Conditions
View All 64 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile